Top

Published in:

01-02-2022 | Thyroid Cancer | Original Article

Potent antitumor activity of novel taxoids in anaplastic thyroid cancer

Authors: Meichen Wang, Changwei Wang, Chao Feng, Wanrong Guo, Huan Chen, Bing Liu, Enxiao Li, Wei Liu, Adam Taouil, Iwao Ojima, Peng Hou

Published in: Endocrine | Issue 2/2022

Abstract

Purpose

Anaplastic thyroid cancer (ATC) is the most aggressive form of thyroid cancers and it is rapidly fatal without any effective therapeutic regimens. There are some clinical trials showing that paclitaxel-based chemotherapy for ATC can achieve a relatively high response rate and low incidence of adverse reaction. The aim of this study was to evaluate potential therapeutic activity of novel taxoids in ATC cells.

Methods

We evaluated antitumor activity of five novel 3′-difluorovinyltaxoids (DFV-taxoids) in anaplastic thyroid cancer cells by a series of in vitro and in vivo experiments. Besides, we also explored the potential mechanism underlying the difference among the taxoids and paclitaxel by molecular docking and tubulin polymerization assays.

Results

Our data showed that these novel DFV-taxoids were more effective than paclitaxel in ATC cell lines and xenografts, as reflected by the inhibition of cell proliferation, colony formation and tumorigenic potential in nude mice, and the induction of G₂/M phase arrest and cell apoptosis. Using tubulin polymerization assays and molecular docking analysis, we found that these DFV-taxoids promoted more rapid polymerization of β-tubulin than paclitaxel.

Conclusions

Our data demonstrate that these novel taxoids exhibit stronger antitumor activity in ATC cells than paclitaxel, thereby providing a promising therapeutic strategy for the patients with ATC.

Available only for authorised users

W. Chen, R. Zheng, P.D. Baade, S. Zhang, H. Zeng, F. Bray, A. Jemal, X.Q. Yu, J. He, Cancer statistics in China, 2015. Ca. Cancer J. Clin. 66, 115–132 (2016). https://doi.org/10.3322/caac.21338CrossRefPubMed

E. Molinaro, C. Romei, A. Biagini, E. Sabini, L. Agate, S. Mazzeo, G. Materazzi, S. Sellari-Franceschini, A. Ribechini, L. Torregrossa, F. Basolo, P. Vitti, R. Elisei, Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. Nat. Rev. Endocrinol. 13, 644–660 (2017). https://doi.org/10.1038/nrendo.2017.76CrossRefPubMed

A.A. Forastiere, Paclitaxel (Taxol) for the treatment of head and neck cancer. Semin. Oncol. 21, 49–52 (1994)PubMed

T.M. Mekhail, M. Markman, Paclitaxel in cancer therapy. Expert. Opin. Pharmacother. 3, 755–766 (2002). https://doi.org/10.1517/14656566.3.6.755CrossRefPubMed

E.K. Rowinsky, The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu. Rev. Med. 48, 353–374 (1997). https://doi.org/10.1146/annurev.med.48.1.353CrossRefPubMed

D.G.I. Kingston, Recent advances in the chemistry of taxol. J. Nat. Prod. 63, 726–734 (2000). https://doi.org/10.1021/np000064nCrossRefPubMed

I. Ojima, J.C. Slater, E. Michaud, S.D. Kuduk, P.Y. Bounaud, P. Vrignaud, M.C. Bissery, J.M. Veith, P. Pera, R.J. Bernacki, Synthesis and structure-activity relationships of new second-generation taxoids. J. Med. Chem. 39, 3889–3896 (1996). https://doi.org/10.1021/jm9604080CrossRefPubMed

I. Ojima, J. Chen, L. Sun, C.P. Borella, T. Wang, M.L. Miller, S. Lin, X. Geng, L. Kuznetsova, C. Qu, D. Gallager, X. Zhao, I. Zanardi, S. Xia, S.B. Horwitz, J.M.-S. Clair, J.L. Guerriero, D. Bar-Sagi, J.M. Veith, P. Pera, R.J. Bernacki, Design, synthesis, and biological evaluation of new-generation taxoids. J. Med. Chem. 51, 3203–3221 (2008). https://doi.org/10.1021/jm800086eCrossRefPubMedPubMedCentral

I. Ojima, J.C. Slater, S.D. Kuduk, C.S. Takeuchi, R.H. Gimi, C.M. Sun, Y.H. Park, P. Pera, J.M. Veith, R.J. Bernacki, Syntheses and structure-activity relationships of taxoids derived from 14 beta-hydroxy-10-deacetylbaccatin III. J. Med. Chem. 40, 267–278 (1997). https://doi.org/10.1021/jm960563eCrossRefPubMed

10.

I. Ojima, X. Wang, Y. Jing, C. Wang, Quest for efficacious next-generation taxoid anticancer agents and their tumor-targeted delivery. J. Nat. Prod. 81, 703–721 (2017). https://doi.org/10.1021/acs.jnatprod.7b01012CrossRef

11.

M.I. Nicoletti, T. Colombo, C. Rossi, C. Monardo, S. Stura, M. Zucchetti, A. Riva, P. Morazzoni, M.B. Donati, E. Bombardelli, M. D’Incalci, R. Giavazzi, IDN5109, a taxane with oral bioavailability and potent antitumor activity. Cancer Res. 60, 842–846 (2000)PubMed

12.

Q. Yang, M. Ji, H. Guan, B. Shi, P. Hou, Shikonin inhibits thyroid cancer cell growth and invasiveness through targeting major signaling pathways. J. Clin. Endocrinol. Metab. 98, 1909–1917 (2013). https://doi.org/10.1210/jc.2013-2583CrossRef

13.

K.A. Johnson, G.G. Borisy, Kinetic analysis of microtubule self-assembly in vitro. J. Mol. Biol. 117, 1–31 (1977). https://doi.org/10.1016/0022-2836(77)90020-1CrossRefPubMed

14.

R.C. Weisenberg, Microtubule formation in vitro in solutions containing low calcium concentrations. Science 177, 1104–1105 (1972). https://doi.org/10.1126/science.177.4054.1104CrossRefPubMed

15.

M.L. Shelanski, F. Gaskin, C.R. Cantor, Microtubule assembly in the absence of added nucleotides. Proc. Natl Acad. Sci. USA. 70, 765–768 (1973). https://doi.org/10.1073/pnas.70.3.765CrossRefPubMedPubMedCentral

16.

O. Trott, A.J. Olson, Autodock vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31, 455–461 (2010). https://doi.org/10.1002/jcc.21334CrossRefPubMedPubMedCentral

17.

M.D. Hanwell, D.E. Curtis, D.C. Lonie, T. Vandermeersch, E. Zurek, G.R. Hutchison, Avogadro: an advanced semantic chemical editor, visualization, and analysis platform. J. Cheminform. 4, 17 (2012). https://doi.org/10.1186/1758-2946-4-17CrossRefPubMedPubMedCentral

18.

T.A. Halgren, Merck molecular force field. 3. Molecular geometries and vibrational frequencies for mmff94. J. Comput. Chem. 17, 553–586 (1996). https://doi.org/10.1002/(SICI)1096-987X(199604)17:5/6<553::AID-JCC3>3.0.CO;2-TCrossRef

19.

T.A. Halgren, Merck molecular force field. 1. Basis, form, scope, parameterization, and performance of mmff94. J. Comput. Chem. 17, 490–519 (1996). https://doi.org/10.1002/(SICI)1096-987X(199604)17:5/6<490::AID-JCC1>3.0.CO;2-PCrossRef

20.

T.A. Halgren, Merck molecular force field. 5. Extension of mmff94 using experimental data, additional computational data, and empirical rules. J. Comput. Chem. 17, 616–641 (1996). https://doi.org/10.1002/(SICI)1096-987X(199604)17:5/6<616::AID-JCC5>3.0.CO;2-XCrossRef

21.

T.A. Halgren, R.B. Nachbar, Merck molecular force field. 4. Conformational energies and geometries for mmff94. J. Comput. Chem. 17, 587–615 (1996). https://doi.org/10.1002/(SICI)1096-987X(199604)17:5/6<587::AID-JCC4>3.0.CO;2-QCrossRef

22.

J. Gasteiger, M.A. Marsili, A New model for calculating atomic charges in molecules. Tetrahedron Lett. 19, 3181–3184 (1978). https://doi.org/10.1016/S0040-4039(01)94977-9CrossRef

23.

J. Gasteiger, M. Marsili, Iterative partial equalization of orbital electronegativity—a rapid access to atomic charges. Tetrahedron Lett. 36, 3219–3228 (1980). https://doi.org/10.1016/0040-4020(80)80168-2CrossRef

24.

E.F. Pettersen, T.D. Goddard, C.C. Huang, G.S. Couch, D.M. Greenblatt, E.C. Meng, T.E. Ferrin, Ucsf chimera - a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605–1612 (2004). https://doi.org/10.1002/jcc.20084CrossRefPubMed

25.

D.J. Kingston, S. Bane, J.P. Snyder, The taxol pharmacophore and the T-taxol bridging principle. Cell Cycle 4, 279–289 (2005)CrossRef

26.

J. Zhou, P. Giannakakou, Targeting microtubules for cancer chemotheraphy. Curr. Med. Chem. 5, 65–71 (2005). https://doi.org/10.2174/1568011053352569CrossRef

27.

M.A. Jordan, R.J. Toso, D. Wilson, L. Thrower, Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc. Natl Acad. Sci. USA. 90, 9552–9556 (1993). https://doi.org/10.1073/pnas.90.20.9552CrossRefPubMedPubMedCentral

28.

J. Gerdes, U. Schwab, H. Lemke, H. Stein, Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J. Cancer 31, 13–20 (1983). https://doi.org/10.1002/ijc.2910310104CrossRefPubMed

29.

E. Nogales, S.G. Wolf, K.H. Downing, Structure of the α, β- tubulin dimer by electron crystallography. Nature 391, 199–203 (1998). https://doi.org/10.1038/34465CrossRefPubMed

30.

J. Löwe, H. Li, K.H. Downing, E. Nogales, Refined structure of α, β-tubulin at 3.5 Å resolution. J. Mol. Biol. 313, 1045–1057 (2001). https://doi.org/10.1006/jmbi.2001.5077CrossRefPubMed

31.

M. Jordan, L. Wilson, Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 4, 253–265 (2004). https://doi.org/10.1038/nrc1317CrossRefPubMed

32.

C. Wang, X. Wang, Y. Sun, A.K. Taouil, S. Yan, G.I. Botchkina, I. Ojima, Design, synthesis and SAR study of 3rd-generation taxoids bearing 3-CH₃, 3-CH₃O and 3-CHF₂O groups at the C₂-benzoate position. Bioorg. Chem. 95, 103523 (2020). https://doi.org/10.1016/j.bioorg.2019.103523CrossRefPubMed

33.

N. Howlader, A.M. Noone, M. Krapcho, D. Miller, A. Brest, M. Yu, J. Ruhl, Z. Tatalovich, A. Mariotto, D.R. Lewis, H.S. Chen, E.J. Feuer, K.A. Cronin. SEER Cancer Statistics Review, 1975–2017. National Cancer Institute. https://seer.cancer.gov/csr. Accessed 15 April 2020

34.

K. Ain, M. Egorin, P. DeSimone, Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Thyroid 10, 587–594 (2000). https://doi.org/10.1089/thy.2000.10.587CrossRefPubMed

35.

H.T. Higashiyama, Y. Ito, M. Hirokawa, M. Fukushima, T. Uruno, A. Miya, F. Matsuzuka, A. Miyauchi, Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma. Thyroid 20, 7–14 (2010). https://doi.org/10.1089/thy.2009.0115CrossRefPubMed

36.

C. Jing, Z. Gao, R. Wang, Z. Yang, B. Shi, P. Hou, Lenvatinib enhances the antitumor effects of paclitaxel in anaplastic thyroid cancer. Am. J. Cancer Res. 7, 903–912 (2017)PubMedPubMedCentral

37.

S.Y. Kim, S.M. Kim, H. Chang, H.S. Chang, C.S. Park, Y.S. Lee, Synergistic anticancer activity of sorafenib, paclitaxel, and radiation therapy on anaplastic thyroid cancer in vitro and in vivo. Head. Neck 42, 3678–3684 (2020). https://doi.org/10.1002/hed.26431CrossRefPubMed

38.

S.H. Kim, J.G. Kang, C.S. Kim, S.H. Ihm, M.G. Choi, H.J. Yoo, S.J. Lee, Cytotoxic effect of celastrol alone or in combination with paclitaxel on anaplastic thyroid carcinoma cells. Tumor Biol. 39, 1010428317698369 (2017). https://doi.org/10.1177/1010428317698369CrossRef

39.

M.E. Cabanillas, M.D. Williams, G.B. Gunn, S.P. Weitzman, L. Burke, N.L. Busaidy, A.K. Ying, Y.H. Yiin, W.N. William, C. Lu, S.Y. Lai, Facilitating anaplastic thyroid cancer specialized treatment: a model for improving access to multidisciplinary care for patients with anaplastic thyroid cancer. Head. Neck 39, 1291–1295 (2017). https://doi.org/10.1002/hed.24784CrossRefPubMed

Title: Potent antitumor activity of novel taxoids in anaplastic thyroid cancer
Authors: Meichen Wang
Changwei Wang
Chao Feng
Wanrong Guo
Huan Chen
Bing Liu
Enxiao Li
Wei Liu
Adam Taouil
Iwao Ojima
Peng Hou
Publication date: 01-02-2022
Publisher: Springer US
Keywords: Thyroid Cancer
Thyroid Cancer
Thyroid Cancer
Published in: Endocrine / Issue 2/2022
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-021-02880-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2022

Regenerative approaches to preserve pancreatic β-cell mass and function in diabetes pathogenesis

High-dose dexamethasone suppression test is inferior to pituitary dynamic enhanced MRI in the differential diagnosis of ACTH-dependent Cushing’s syndrome

Quantitative T1 mapping MRI for the assessment of extraocular muscle fibrosis in thyroid-associated ophthalmopathy

Acromegaly disease activity according to ACRODAT®, a cross-sectional study in Spain: ACROVAL study

The genetic polymorphisms of key genes in WNT pathway (LRP5 and AXIN1) was associated with osteoporosis susceptibility in Chinese Han population

Outcome of parathyroid function after total thyroidectomy when calcium supplementation is administered routinely versus exclusively to symptomatic patients: A prospective randomized clinical trial

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage